Date:2/17/2011

essary clinical results and regulatory approvals for services and products in development, and our new services and products may not achieve market acceptance, investments in new technologies and acquisitions of products or distribution rights may not be successful, extensive government regulation may adversely affect our ability to develop and market services and products, if we are not successful in expanding our business activities in international markets, we may be unable to increase our revenues, we are not insured against all potential losses, and natural disasters or other catastrophes could adversely affect our business, we may be unable to obtain adequate insurance at a reasonable cost, if at all, and we are dependent on key personnel. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K to be filed on or around February 18, 2011 for the year ended December 31, 2010.Media Contacts:D. Ashley LeeExecutive Vice President, Chief Financial Officer and  Chief Operating OfficerPhone: 770-419-3355Chris MittendorfEdelmanPhone: 212-704-8134CRYOLIFE, INC. AND SUBSIDIARIESFinancial Highlights(In thousands, except per share data)Three Months EndedTwelve Months EndedDecember 31,December 31,2010200920102009Revenues:(Unaudited)(Audited)Preservation services

$
4,025

$
3,784$
59,724

$
56,456Products

15,094

14,49356,370

54,162Other

103

338551

1,067Total revenues29,22228,615116,645111,685Cost of preservation services and products:Preservation services

8,546

8,34635,868

32,767Products

3,091

2,67212,409

9,150Total cost of preservation services and products11,63711,01848,27741,917Gross margin17,58517,59768,36869,768Operating expenses:General, administrative, and marketing

12,201

12,58549,064

50,025Research and development

<
'/>"/>

SOURCE CryoLife, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine technology :

1. CryoLife Announces Release Date and Teleconference Call Details for 2010 Fourth Quarter and Year End Financial Results
2. CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
3. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
4. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
5. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
6. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
7. CryoLife Provides Initial 2010 Financial Guidance
8. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
9. CryoLife to Present at Upcoming Investor Conferences in New York
10. CryoLife Reports Record Quarterly Revenues of $28.2 Million
11. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)